First-in-Human Trial for GSK4425689A Monoclonal Antibody Initiated
A first-in-human dose-escalation study for GSK4425689A is underway, focusing on safety and pharmacokinetics.
Asset / Drug
Drug and asset intelligence for GSK4425689A with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Monoclonal Antibody
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.